Design and characterization of a new peptide vector for short interfering RNA delivery (2015)
Sequence: Ac-GLWRAWLWKAFLASNWRRLLRLLR-NH2
| Experiment Id | EXP001573 |
|---|---|
| Paper | Design and characterization of a new peptide vector for short interfering RNA delivery |
| Peptide | GL1 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | no |
| Peptide Concentration | |
| Rna Concentration | 100 nM for uptake assays (4 h); 50 nM for gene silencing assays (52 h total) |
| Mixing Ratio | MR 40:1 (peptide:siRNA molar ratio) |
| Formulation Format | noncovalent peptide/siRNA nanocomplex |
| Formulation Components | GL1 + siRNA (electrostatic + hydrophobic interactions) |
| Size Nm | 80.00 |
| Zeta Mv | 27.00 |
| Model Scope | in_vitro |
| Model Type | in vitro (serum-free) |
| Cell Lines Or Primary Cells | CHO-K1 (Chinese hamster ovary) |
| Animal Model | |
| Administration Route | |
| Output Type | Uptake (FACS % and microscopy) + functional gene knockdown (qRT-PCR) |
| Output Value | Uptake ~95% at MR40 (serum-free); GAPDH mRNA knockdown ~58% (MR40) |
| Output Units | |
| Output Notes | Cy3-GAPDH siRNA shows perinuclear/cytosolic localization by fluorescence microscopy; GL1 yields higher uptake than Lipofectamine 2000 in serum-free conditions but lower silencing, attributed to endosomal retention. |
| Toxicity Notes | Cell viability >85% across tested molar ratios; higher than Lipofectamine 2000 (~70%) |
| Curation Notes |